West Pharmaceutical Services - WST Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" WST shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WST, but not buy additional shares or sell existing shares.
View WST analyst ratings or view top-rated stocks.

5 equities research analysts have issued twelve-month price targets for West Pharmaceutical Services' stock. Their WST share price forecasts range from $250.00 to $315.00. On average, they predict the company's share price to reach $266.25 in the next twelve months. This suggests that the stock has a possible downside of 1.0%.
View analysts price targets for WST or view top-rated stocks among Wall Street analysts.

West Pharmaceutical Services' stock was trading at $235.35 at the start of the year. Since then, WST stock has increased by 14.3% and is now trading at $269.05.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our WST earnings forecast.

West Pharmaceutical Services will be holding an earnings conference call on Thursday, February 16th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

West Pharmaceutical Services, Inc. (NYSE:WST) posted its quarterly earnings data on Thursday, October, 28th. The medical instruments supplier reported $2.06 earnings per share for the quarter, beating analysts' consensus estimates of $1.80 by $0.26. The medical instruments supplier earned $706.50 million during the quarter, compared to analyst estimates of $687.09 million. West Pharmaceutical Services had a net margin of 21.68% and a trailing twelve-month return on equity of 28.15%. The business's revenue was up 28.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.15 EPS.
Read the conference call transcript.

West Pharmaceutical Services announced a quarterly dividend on Tuesday, December 13th. Shareholders of record on Wednesday, January 25th will be given a dividend of $0.19 per share on Wednesday, February 1st. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date is Tuesday, January 24th.
Read our dividend analysis for WST.

West Pharmaceutical Services (NYSE:WST) pays an annual dividend of $0.76 per share and currently has a dividend yield of 0.28%. The company has been increasing its dividend for 30 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 9.17%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, WST will have a dividend payout ratio of 10.48% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for WST.

107 employees have rated West Pharmaceutical Services Chief Executive Officer Eric M. Green on Glassdoor.com. Eric M. Green has an approval rating of 75% among the company's employees. 60.0% of employees surveyed would recommend working at West Pharmaceutical Services to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Walt Disney (DIS), Home Depot (HD), Visa (V), Alibaba Group (BABA), McDonald's (MCD), Netflix (NFLX) and PepsiCo (PEP).

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

West Pharmaceutical Services' stock is owned by a number of institutional and retail investors. Top institutional investors include ProShare Advisors LLC (0.95%), Riverbridge Partners LLC (0.69%), Congress Asset Management Co. MA (0.51%), AustralianSuper Pty Ltd (0.45%), Sumitomo Mitsui Trust Holdings Inc. (0.40%) and Assenagon Asset Management S.A. (0.31%). Insiders that own company stock include Annette F Favorite, David A Montecalvo, Eric Mark Green, George Lloyd Miller, Patrick J Zenner, Quintin J Lai and Silji Abraham.
View institutional ownership trends.

Shares of WST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WST stock can currently be purchased for approximately $269.05.

West Pharmaceutical Services (NYSE:WST) has a market capitalization of $19.92 billion and generates $2.83 billion in revenue each year. The medical instruments supplier earns $661.80 million in net income (profit) each year or $8.29 on an earnings per share basis.

The company employs 10,065 workers across the globe.

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The official website for the company is www.westpharma.com. The medical instruments supplier can be reached via phone at (610) 594-2900, via email at quintin.lai@westpharma.com, or via fax at 800-345-9800.